.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Argus Health
McKinsey
Covington
Novartis
UBS
Fish and Richardson
Daiichi Sankyo
Queensland Health
Cerilliant

Generated: July 25, 2017

DrugPatentWatch Database Preview

Conivaptan hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for conivaptan hydrochloride and what is the scope of conivaptan hydrochloride freedom to operate?

Conivaptan hydrochloride
is the generic ingredient in two branded drugs marketed by Cumberland Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Conivaptan hydrochloride has twenty-nine patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for Generic Name: conivaptan hydrochloride

Tradenames:2
Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list47
Clinical Trials: see list2,269
Patent Applications: see list76
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:conivaptan hydrochloride at DailyMed

Pharmacology for Ingredient: conivaptan hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms
VAPRISOL
conivaptan hydrochloride
INJECTABLE;IV (INFUSION)021697-001Dec 29, 2005DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Cumberland Pharms
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
conivaptan hydrochloride
INJECTABLE;IV (INFUSION)021697-002Oct 8, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: conivaptan hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,856,564 Condensed benzazepine derivative and pharmaceutical composition thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: conivaptan hydrochloride

Country Document Number Estimated Expiration
Spain2198418► Subscribe
Russian Federation2129123► Subscribe
New Zealand268671► Subscribe
Australia3990697► Subscribe
Finland960260► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Accenture
Cantor Fitzgerald
Baxter
McKinsey
Novartis
Moodys
Daiichi Sankyo
Cipla
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot